Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Dimopoulos, Meletios A, Prof, Moreau, Philippe, Prof, Palumbo, Antonio, Prof, Joshua, Douglas, Prof, Pour, Ludek, Prof, Hájek, Roman, Prof, Facon, Thierry, Prof, Ludwig, Heinz, Prof, Oriol, Albert, Prof, Goldschmidt, Hartmut, Prof, Rosiñol, Laura, Prof, Straub, Jan, Prof, Suvorov, Aleksandr, Prof, Araujo, Carla, Prof, Rimashevskaya, Elena, Prof, Pika, Tomas, Prof, Gaidano, Gianluca, Prof, Weisel, Katja, Prof, Goranova-Marinova, Vesselina, Prof, Schwarer, Anthony, Prof, Minuk, Leonard, Prof, Masszi, Tamás, Prof, Karamanesht, Ievgenii, Prof, Offidani, Massimo, Prof, Hungria, Vania, Prof, Spencer, Andrew, Prof, Orlowski, Robert Z, MD, Gillenwater, Heidi H, MD, Mohamed, Nehal, PhD, Feng, Shibao, PhD, Chng, Wee-Joo, Prof
Published in The lancet oncology (01.01.2016)
Published in The lancet oncology (01.01.2016)
Get full text
Journal Article
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
Delforge, Michel, Prof, Bladé, Joan, Prof, Dimopoulos, Meletios A, Prof, Facon, Thierry, Prof, Kropff, Martin, MD, Ludwig, Heinz, Prof, Palumbo, Antonio, Prof, Van Damme, Philip, MD, San-Miguel, Jesús F, Prof, Sonneveld, Pieter, Prof
Published in The lancet oncology (01.11.2010)
Published in The lancet oncology (01.11.2010)
Get full text
Journal Article